Save the Date
November 18 – 19, 2020 • Harvard Medical School, Boston, MA
Below, please find a list of head-shots and biographical descriptions of confirmed speakers for the 15th Annual Personalized Medicine Conference.
Edward Abrahams, Ph.D.
Personalized Medicine Coalition
Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
Bonnie J. Addario
GO2 Foundation for Lung Cancer
Bonnie has been an activist, advocate, educator and change agent empowering patients and giving them a strong voice in the fight against lung cancer since receiving a stage 3B diagnosis more than a decade ago. Although thrust into a role that she had never envisioned for herself, she embraced it and now considers it to be her second career and a personal calling. Recognizing the critical need for education, empowerment, advocacy and research to help patients and families, especially those without resources and support, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006, and then went on to found the Addario Lung Cancer Medical Institute (ALCMI) with her husband, Tony Addario, in 2008. Bonnie’s business acumen and skills honed in her first career as President of Olympian Oil Company and Commercial Fueling Network (CFN), as Past President of the CA Independent Oil Marketers Association (CIOMA) and as a community activist serving on diverse boards have all contributed to her work at ALCF in developing business strategies and being the Foundation’s patient voice at national/international conferences, on panels and boards, and to industry leaders, clinicians and policy makers. Bonnie’s personal interests include collecting wine, travel, sports (Go SF Giants!) and spending time with family and friends at Lake Tahoe.
Wadha Al-Muftah, M.D., Ph.D.
Manager, Clinical Initiatives
Qatar Genome Program
Dr. Wadha Al-Muftah is the Manager of the Clinical Initiatives at Qatar Genome programme (QGP), and Instructor in Genomic Medicine (courtesy) at Weill Cornell Medicine Qatar (WCM-Q). She holds a Ph.D. in Clinical Medicine Research from Imperial College London (ICL) in the United Kingdome and M.D from Arabian Gulf University in the Kingdome of Bahrain.
Dr Al-Muftah works in QGP since late 2016 and she leads the genome interpretation project. The project is focused on establishing computational genomics platform providing interpretation/ clinical reporting solutions, supporting high throughput panels, whole exomes and whole genomes for general wellness in phase I; pharmacogenomics in phase II; hereditary diseases and oncology in phase III.
Her main research interest focuses on early detection of diabetes and prevention through the identification of genetic factors contributing to the development of type 2 diabetes among the Qatari population, for which she has received funding as a principal investigator for the Qatar Diabetes Prevention Program. Qatar National Research Fund (QNRF), the main research funding body in Qatar, awarded this project.
Dr Wadha earned her PhD from ICL, her thesis interrogated genetics, epigenetic and environmental connections causative for type 2 diabetes (T2D) in Qatari families. She was trained in the department of genomic of common disease at ICL and bioinformatics core at WCM-Q, where she used the state-of-art of sequencing technologies including whole genome sequencing and genome-wide methylation arrays. Dr Al-Muftah has published multiple scientific articles in leading journals and presented her work in international conferences.
Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational Medicine
Toni is an M.D., Ph.D. who specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research.
After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute where he became Director of the Neurosciences Research Program.
He has also been extremely active in the field of policy-making and held positions as the Director of the Spanish National Institute of Health Carlos III, creating the national program for personalized medicine. He has also been the CEO of the Bellvitge Hospital, one of the most important University hospitals in Spain, as well as the Director General for Research and Innovation at the Catalan Ministry of Health.
Toni is now the Scientific Director at EATRIS, the European Advanced Infrastructure for Translational Research.
Cynthia A. Bens
Senior Vice President, Public Policy
Personalized Medicine Coalition
Cynthia A. Bens, Senior Vice President, Public Policy at PMC, leads the Coalition’s policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. In collaboration with PMC’s Senior Vice President, Science Policy, Bens is responsible for implementing research, regulatory and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
Before joining PMC, Bens was the Vice President of Public Policy at the Alliance for Aging Research. Bens guided the Alliance’s federal policy work, represented the organization in multiple national coalitions and directed all aspects of coalitions led by the Alliance. She spent more than a decade at the Alliance advancing policies to expedite the development of interventions for neurological diseases and physical frailty; to remove access barriers for cardiovascular disease treatments; and to enhance the quality of care for older adults living with multiple chronic conditions.
Strategic Advisor; Government Fellow
Rwanda Biomedical Center; World Economic Forum
Jane Cheshire Gilbert, C.P.A., C.G.B.A.
Director, Retiree Health Care
Teachers' Retirement System of Kentucky
Jane Gilbert is the Director of Retiree Health Care for the Teachers’ Retirement System of the State of Kentucky (TRS) and has served TRS retirees since April 2002. She manages two retiree health plans covering 48,000 retirees. She also serves as a leader in the areas of health insurance cost containment, project management, risk management and federal health care solutions.
Ms. Gilbert served in management and directorship positions for a Louisville Kentucky law firm and cost containment company, The Rawlings Company, from 1989 through 2002. Prior to serving at The Rawlings Company, she worked as an accountant for a national CPA firm.
Ms. Gilbert graduated with honors from Bellarmine University in Louisville, Kentucky, with a Bachelor of Arts in Accounting in 1987, became a CPA in 1992, and achieved her Certified Government Benefits Administrator (CGBA) designation in 2012. Ms. Gilbert currently serves on the Board of the State and Local Government Benefits Association and is a proud member of the Public Sector Healthcare Roundtable.
William S. Dalton, M.D., Ph.D.
Founder, Executive Chairman
Dr. William (Bill) S. Dalton is Founder and Executive Chair of M2Gen, a national biotechnology subsidiary of the Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to joining Moffitt, Dr. Dalton was the Dean of the University of Arizona College of Medicine. His research interests include development of information systems to allow aggregation, organization, and sharing of patient data in real time to enhance discovery and delivery of evidenced-based precision medicine. For his leadership in the area of personalized medicine, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and computer/information networking. He has served on numerous not-for-profit boards, including the National Board of the Leukemia and Lymphoma Society; he is the past-Chair of the Personalized Medicine Coalition and is the current Board Chair of the Institute of Human and Machine Cognition. He is also the past-President of the Association of American Cancer Institutes.
Michael Doney, M.D., Ph.D., M.S.
Head of Medical Affairs
Dr. Doney is head of Medical Affairs at Color. Most recently, Michael served as VP, Medical Affairs, Medical Director and Principal Investigator within the Health Nucleus at Human Longevity, Inc. Michael has over 15 years of clinical practice experience in emergency medicine and emergency public health initiatives and served in leadership positions at the US Centers for Disease Control & Prevention (CDC) and within Medical Affairs in the pharmaceutical industry. Michael completed his residency in emergency medicine at UC-San Diego and a fellowship in international emergency medicine at The George Washington University. He holds graduate degrees in molecular genetics and public health.
Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer
Immatics US Inc.
Stephen L. Eck M.D., Ph.D., is a Hematologist/Oncologist with extensive experience in the development of pharmaceuticals and their companion diagnostics. He is currently Chief Medical Officer of Immatics (Houston, TX), which develops novel cancer immunotherapeutics. He is Chairman of the Board of the Personalized Medicine Coalition (Washington D.C.). He also serves on the Board of Directors of Luminex Corporation (Austin, TX) and Cirulogene (Birmingham, AL), which develop and market medical diagnostics. He also serves on the Board of Trustees of the Keck Graduate Institute (Claremont, CA) and on the Board of Directors of the Central Pennsylvania Clinic (Belleville, PA), which serves patients with rare genetic disorders.
Previously, Dr. Eck has held a variety of industry leadership positions at Aravive Biologics, Astellas Pharma, Lilly and Pfizer and served on the faculty of the University of Michigan School of Medicine and the University of Pennsylvania School of Medicine. He holds a B.S. degree from Kalamazoo College, a M.D. degree from the University of Mississippi and a Ph.D. from Harvard University.
Sarah K. Emond, M.P.P.
Executive Vice President, Chief Operating Officer
Institute for Clinical and Economic Review
With over 20 years of experience in the business and policy of health care, Sarah leads the strategic operations of the Institute for Clinical and Economic Review, a leading non-profit health policy research organization, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, stakeholder engagement, and finances.
Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a health care communications firm. Sarah began her health care career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor’s degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based health care. Sarah recently learned to ski and is proud that she hasn’t broken any bones doing so, and has completed seven half-marathons since she took up long-distance running in 2013.
Roy Gandolfi, M.D.
Dr. Gandolfi is a Medical Director at SelectHealth, a not-for-profit health plan serving more than 900,000 members in Utah, Idaho, and Nevada. SelectHealth and Intermountain Healthcare form a not-for-profit health system committed to Helping People Live the Healthiest Lives Possible.
Dr. Gandolfi’s responsibilities include developing and implementing medical policies. Dr. Gandolfi is deeply involved in genomic utilization and has established a medical oncology quality project which promotes pathway compliance and genetic evaluation.
Dr. Gandolfi received his bachelor’s and medical degrees from the University of Michigan. He is a practicing Internist in a large
multi-specialty clinic in Salt Lake City. He is an Adjunct Associate Professor of Medicine at the University of Utah School of Medicine.
Scott Gottlieb, M.D.
American Enterprise Institute
Scott Gottlieb, M.D., is a resident fellow at the American Enterprise Institute (AEI). He returned to AEI in 2019 after serving as the 23rd commissioner of the Food and Drug Administration (FDA). At AEI, he continues his work on improving public health through entrepreneurship and medical innovation and on expanding regulatory approaches to maintain patient and physician autonomy.
At FDA, Dr. Gottlieb focused on a wide variety of issues, including drug pricing, medical product innovation, food safety, vaccination, and tobacco and vaping. He advanced new policies to address opioid addiction, working to rationalize prescribing as a way to reduce the rate of new addiction. He helped make the regulatory process for the development and review of novel drug and medical devices more efficient, including the approval of the first gene-therapy-based cancer treatment. He also presided over a record number of novel drug and medical device approvals first in 2017, and then breaking that record in 2018.
Assaf Halevy is the founder and chief executive officer of 2bPrecise, LLC, a genomics and precision medicine platform. Halevy leads an international team dedicated to bridging the final mile between the science of genomics and making that data useful at the point of care.
He joined Allscripts as senior vice president of products and business development in 2013 when the company acquired Israel-based dbMotion. An initial inventor and co-founder of dbMotion, Halevy helped develop the leading clinical integration and population health management platforms in the industry today.
Halevy served in key leadership roles that influenced dbMotion’s rapid growth and success. As the company expanded, Halevy moved to Pittsburgh to build an operational infrastructure in the U.S., ultimately introducing semantic interoperability to the American healthcare market in 2005. The platform was adopted by dozens of leading provider organizations, ranked number one interoperability solution in KLAS for several years and honored with many industry awards.
With 13 patents pending in the areas of actionable clinical integration, interoperability and precision medicine, Halevy leverages his industry expertise by evaluating strategic alliances and partnerships for U.S. and international markets. Halevy was invited to participate in several U.S. government activities and contribute in an HHS privacy committee task force. In 2016, he was part of a small selective group of executives invited to the White House by Vice President Joe Biden to discuss the future of interoperability.
Halevy holds a Bachelor of Science degree, with honors, in computer science from the Academic College of Tel Aviv-Jaffa and Tel Aviv University, as well as Genomics and Genetics certification from Stanford University.
Richard Hamermesh, D.B.A.
Harvard Business School Kraft Precision Medicine Accelerator
Richard Hamermesh is a Senior Fellow at the Harvard Business School, where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the Faculty Co-Chair of the Kraft Precision Medicine Accelerator. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the course head for the required first-year course, The Entrepreneurial Manager.
From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.
Richard is also an active investor and entrepreneur, having participated as a principal, director and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton Schools Foundation and served on the editorial board of the Harvard Business Review.
Richard is the author or co-author of five books, including New Business Ventures and The Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published more than 100 case studies and numerous articles, including his recent publications “What Precision Medicine Can Learn from the NFL” and “One Obstacle to Curing Cancer: Patient Data isn’t Shared.”
Erja Heikkinen, Ph.D.
Science Policy Director
General Ministry of Education and Culture, Finland
Dr. Heikkinen has been with the Ministry of Education and Culture in Finland since 2005 active in national and international science policy. She currently holds the leadership position in the Ministry addressing higher education policy and research and its implementation as part of the National Health Sector Growth Strategy. Erja’s team has participated in drafting legislation for genome and biobank data and sample use for both research and healthcare.
In 2001 Dr. Heikkinen joined the National Technology Agency, Tekes where her tasks involved funding of private and public organizations in projects combining bioscience, medicine, and ICT. Prior to Tekes, Erja was at the Finnish National High-Performance Computing Center for Science, CSC-IT, responsible for Bioinformatics services. And, immediately before CSC-IT, she developed and served at the newly established graduate school system of Finland in the field of biomedicine.
Dr. Heikkinen graduated from the University of Oulu, Finland with a PhD in population genetics. She is a docent in evolutionary biology at the University of Helsinki, Finland. Erja completed her post-doctoral training at the University of Tübingen, Germany and at the University of California at Davis. She also completed two non-degree higher education programs, in economics and in higher education administration, management and economics.
Kris Joshi, Ph.D.
Executive Vice President; President, Network Solutions
Mr. Joshi is Executive Vice President and President, Network Solutions for Change Healthcare. He initially joined Change Healthcare as Executive Vice President, Products in December 2013. Prior to that, Mr. Joshi was Global Vice President for health care product strategy for the Health Sciences Global Business Unit of the Oracle Corporation. He helped launch the health sciences business unit and successfully led two acquisitions for Oracle in the life sciences space. Before joining Oracle, Mr. Joshi served in senior strategy roles in IBM’s Global Sales and Distribution organization. Prior to that, Mr. Joshi was with McKinsey and Company, where he served Fortune 500 clients on strategy issues.
Mr. Joshi holds a Bachelor’s degree in mathematics from Caltech, and a Ph.D. in physics from MIT.
Carl June, M.D.
Richard W. Vague Professor in Immunotherapy
University of Pennsylvania
Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland, from 1978 – 1979, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in internal medicine and medical oncology.
Steven Kafka, Ph.D.
Partner; Executive Chairman
Third Rock Ventures; Thrive Earlier Detection
Steve Kafka is a partner at Third Rock Ventures, where he brings more than 20 years of operating experience in building therapeutics and molecular diagnostic companies dedicated to transformational patient impact. At TRV, Steve was the founding CEO and currently serves as executive chairman of Thrive Earlier Detection, a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Most recently, Steve was president and chief operating officer at Foundation Medicine, Inc., which was sold to Roche in 2018.
Karen Knudsen, Ph.D.
Director, Sidney Kimmel Cancer Center
Hilary Koprowski Endowed Professor and Chair, Department of Cancer Biology
Professor, Department of Cancer Biology, Urology, Radiation Oncology, and Medical Oncology
Karen E. Knudsen, PhD, is EVP of Oncology Services and Enterprise Director of the Sidney Kimmel Cancer Center (SKCC) at Jefferson, one of only 70 National Cancer Institute designated centers. Dr. Knudsen oversees cancer research and cancer patient care across Jefferson Health, and SKCC is consistently ranked as one of the top centers for cancer care in the nation. Dr. Knudsen also serves as Chair of the Department of Cancer Biology at the Thomas Jefferson University, and holds joint appointments in the departments of Urology, Medical Oncology, and Radiation Oncology. Dr. Knudsen’s expertise is in developing new means to treat advanced prostate cancer, and discovering genetic alterations that contribute to disease progression. Dr. Knudsen is active in the field, serving as the Editor-in-Chief of Molecular Cancer Research, as President-Elect of AACI, holds leadership roles in national organizations including ASCO, and serves on the NCI Board of Scientific Advisors.
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics
Harvard Medical School
Dr. Raju Kucherlapati is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital. Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on cancer genetics.
Raju is an Independent Non-Executive Director at PureTech Health and sits on PureTech Health’s Scientific Advisory Board. He was a founder and formerly a Board member of Abgenix (acquired by Amgen), and Millennium Pharmaceuticals (acquired by Takeda).
Dr. Kucherlapati’s laboratory at Harvard Medical School is involved in cloning and characterization of human disease genes with a focus on human syndromes with a significant cardiovascular involvement, use of genetic/genomic approaches to understand the biology of cancer and the generation and characterization of genetically modified mouse models for cancer and other human disorders.
During 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University. He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science. He was a member of Presidential Commission for the Study of Bioethical Issues during the Obama administration. Dr. Kucherlapati received his BS and MS in Biology from universities in India, and he received his PhD from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.
Peter Maag, Ph.D.
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis’ headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various health care and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD and the Personalized Medicine Coalition. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his Ph.D. from the University of Berlin, Germany.
Anne-Marie Martin, Ph.D.
Senior Vice President, Global Health of Precision Medicine
Novartis Pharmaceuticals Corporation
As SVP, Global Head of Precision Medicine, Anne-Marie is responsible for the development, implementation and execution of the Precision Medicine Strategy to support clinical development, registration and commercialization in Novartis Oncology. Since joining Novartis in 2016, Anne-Marie has led the development and approval of companion diagnostics in support of 3 clinical assets including midostaurin for Flt3 mutated AML, the first BRAF NGS assay for tafinalr and mekinist in NSCLC and an ALK assay for ceritinib also in NSCLC. In addition, she has led the correlative science associated with all clinical assets in Oncology. Anne-Marie holds a PhD in Microbiology & Immunology from Drexel University (formerly Hahnemann University) in Philadelphia. She has over 19 years of experience in the health care sector. She began her career in cancer research at the University of Pennsylvania. During her time at UPENN, she received funding from the Susan G. Komen Foundation, the Leiomyosarcoma Foundation, Fibro-ossificans Progressiva Foundation and the NIH through a SPORE grant. Anne-Marie assumed the role of Director of Molecular Diagnostics and Immunohistochemistry at Pennsylvania Hospital/UPHS whilst maintaining an adjunct faculty position in the Departments of Haematology and Oncology and Orthopaedic Surgery at UPENN. Subsequently, in 2005 Anne-Marie joined GlaxoSmithKline where she was responsible for designing biomarker strategies for early phase development. In 2006, Anne-Marie assumed the role of Director of Biomarker Research for late stage clinical development in Oncology. In this position, she built a cross-functional, global team to deliver clinical translational research and she built a network of world acclaimed KOLs & pathologists to guide and collaborate on Oncology biomarker research. In 2008, Anne-Marie assumed the role as Global Head, Precision Medicine and Diagnostics. In this capacity she led a global team responsible for the precision medicine strategy in Oncology to deliver all translational research into pipeline opportunities, accounting for over 10 clinical assets and an additional five assets in the first-in-human setting. In addition, she led the development of the companion diagnostic assay that supported the approvals of Tafinlar® and Mekinist™. During her tenure at GSK, Anne-Marie contributed to three NDAs and five sNDAs. From 2014-2015 Anne-Marie led the transition and integration of her team’s work to Novartis. At the completion of the integration she assumed the role of VP, Head of Biomarker Research & Diagnostic Development, Adaptimmune LLC. In this role, Anne-Marie was responsible for ensuring that biomarker research is accurately and appropriately translated into the clinical development strategy and she was accountable for all companion diagnostic development. Anne-Marie has multiple manuscripts published in peer-reviewed journals and she has greater than 50 abstracts resulting in conference presentations.
Howard McLeod, Pharm.D.
DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is chair of the Department of Individualized Cancer Medicine and a State of Florida Endowed Chair in Cancer Research. He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida. Dr. McLeod is chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of China and a Professor at Central South University in Changsha, China. Howard has published over 530 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.
Coriell Life Sciences
As founder and Chief Executive Officer of Coriell Life Sciences (CLS), Mr. Megill led the formation, and successful market launch of CLS as the commercial arm of the Coriell Institute for Medical Research, where he previously served as Chief Information Officer. Under his stewardship, CLS has attained a market leading position in molecular diagnostic interpretation and reporting. The company’s products provide clinical decision support for physicians and pharmacists in the areas of medication management, women’s health, infectious disease and more.
Prior to Coriell, Mr. Megill was with the Rohm and Haas/Dow Chemical Corporation, where he led Enterprise Technology Development and Architecture. There, he spearheaded the implementation of many global-scale, multi-year business technology initiatives, including the Digital Rights and Identity Management program. He also led the cross-company team responsible for integrating all aspects of the technology infrastructure leading up to the $15B acquisition of Rohm and Haas. Mr. Megill also spent 5 years with Willis Towers Watson leading the Business Technology Development department.
Scott earned a dual Bachelor of Arts degree from Drew University and a Master of Business Administration from Villanova University.
Nancy Mendelsohn, M.D.
Chief Medical Officer, Special Needs Initiative
Dr. Mendelsohn is a Senior Physician-Scientist and healthcare leader with an international reputation as a clinical geneticist, researcher, and deep leadership experience across employments. Dr. Mendelsohn’s current role as Chief Medical Officer of the Special Needs Initiative at UnitedHealthcare (UHC) encompasses clinical strategy, leadership and execution in support of UnitedHealth Group’s (UHG) Special Needs Initiative. Dr. Mendelsohn’s accountabilities include efforts to guide and support UHG’s strategic priorities related to genomic medicine working across Optum and UHC.
Prior to her position at UHG Dr. Mendelsohn most recently served as chief of specialty pediatrics at Children’s Minnesota. She has 25 years as a board-certified medical geneticist and a national leader in the clinical genetics community. Dr. Mendelsohn received an undergraduate degree in Molecular Biology from Indiana University and an MD from the University of Missouri in 1987. From 1987 to 1992, she completed a residency in pediatrics and fellowship in medical genetics at Washington University Children’s hospital in St. Louis Missouri. Her first clinical role was as a Public Health Service Pediatrician. She then established a new genetics service at Hennepin County Medical Center, an indigent care hospital as well as at Gillette Children’s Specialty Healthcare, a hospital dedicated to the care of special needs children. In 2003, Dr. Mendelsohn joined the genetics staff at Children’s Minnesota. From 2007 – 2015 she became the Medical Director of the genetics service. She served as the Lead Physician Liaison of Service Excellence for the employed clinicians at Children’s Minnesota, 2012 to 2013. In 2013 Dr. Mendelsohn became the Senior Medical Director of ambulatory specialty care until her promotion to the chief position. Dr. Mendelsohn has more than 50 peer reviewed publications, book chapters and presentations. She has specific clinical expertise in lysosomal storage disorders, has published in the New England Journal of Medicine on this topic, and has served broadly on national committees for the American Academy of Pediatrics (AAP), American College of Medical Genetics & Genomics (ACMGG), and within the state of Minnesota.
Kenna R. Mills Shaw, Ph.D.
MD Anderson Institute for Personalized Cancer Therapy
Dr. Shaw is Executive Director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the U.S. National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
Lincoln Nadauld, M.D., Ph.D.
Chief, Precision Health
Lincoln Nadauld, M.D., PhD., is the Chief of Precision Health at Intermountain Healthcare. Dr. Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With his vision in mind, he oversees the clinical implementation of Precision Genomics across Intermountain’s 24 hospitals and 160 physician clinics. In addition, Dr. Nadauld facilitates genomic research to better understand the human genome. Dr. Nadauld conceived of and is leading the recently announced Heredigene, Population Study. A collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system.
Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics. He remains a visiting scholar at Stanford University, focusing on cancer genomics and personalized medicine. His work has been published extensively and featured in a case study by Harvard Business Review, which discusses Intermountain Precision Genomics’ cutting-edge cancer care approach. Dr. Nadauld participated in the Precision Medicine Initiative Summit and roundtables at the White House with former President Barack Obama. He also participated in former Vice President Biden’s Cancer Moonshot Summit. His work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry. This medal is the highest civilian award to be bestowed by the state of Utah, honors significant contributions to science and technology.
Dr. Nadauld is married with five children and enjoys attending their many activities and events, water sports, fishing, and other athletic pursuits.
Peter J. Neumann, Sc.D.
Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He served as co-chair of the 2nd Panel on Cost-Effectiveness in Health and Medicine. He is the author or co-author of over 250 papers in the medical literature, the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) and co-editor of Cost-Effectiveness in Health and Medicine, 2nd Edition (Oxford University Press, 2016). Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is a member of the editorial advisory board of Health Affairs and the health policy advisory boards for the Congressional Budget Office. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University.
Michael Pellini, M.D., M.B.A.
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017.
He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, Octave Health, Vineti, the Personalized Medicine Coalition, and the Mission Hospital Foundation, in addition to his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health).
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
George Poste, Ph.D., D.Sc.
Director, Complex Adaptive Systems
Arizona State University
Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist, The Complex Adaptive Systems Initiative (CASI) (http://www.casi.asu.edu) at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in
human diseases to develop new diagnostic tests for precision (personalized) medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built The Biodesign Institute at ASU. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a member of the Council for Foreign Relations, and U. S. National Academy of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.
Daryl Pritchard, Ph.D.
Senior Vice President, Science Policy
Personalized Medicine Coalition
Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the PMC, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.
Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council. Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Innovation Organization (BIO).
Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics/NHGRI Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.
Vice President, Global Market Access
Ammar Qadan is currently and since Nov 2016 the Vice President and Global Market Access Lead at Illumina; a company whose mission is “to improve human health by unlocking the power of the genome”. Throughout his career, Ammar has been distinguished as a passionate, innovative, patient-focused Biotech leader who worked in different healthcare industries, multiple global geographies, multiple disease areas/ products in different life-cycle stages. Ammar also worked in different corporate functions ranging from commercial to clinical development. Ammar led or co-led many strategic corporate initiatives. While at Illumina, Ammar built the market access function with exceptional talent across geographies, designed and executed the first value-based contract in Next Generation Sequencing, collaborated with BCBSA on a national program to study genomic testing utilization trends. Before joining Illumina, Ammar was the Vice President and Global Product Team Lead at Halozyme Therapeutics, a Biotech focused on Oncology development. He was instrumental in revamping their lead biomarker-driven oncology program strategy, leading to new clinical development programs and a major partnership. Prior to joining Halozyme, Ammar spent nearly 20 years at Bristol Myers Squibb in roles of increasing complexity where he worked & lived in 6 different countries. Ammar is a Pharmacist by training.
Alissa Resch, Ph.D.
Chief Scientific Officer
Coriell Institute for Medical Research
Dr. Alissa Resch, Ph.D. is the Chief Scientific Officer at the Coriell Institute for Medical Research where she oversees the scientific and operational functions of the biobank. She is responsible for all federal, private and commercially funded repository grants and contracts and works closely with the business development and research teams to onboard new projects and collaborations. Prior to her role as Chief Scientific Officer, Alissa served as Director of Biobanking Operations. In this role, she supervised the project management team to ensure all project deliverables and biobanking best practices were met or exceeded. Before joining Coriell, Dr. Resch was a faculty member at the University of Connecticut where she conducted research in genomics and RNA biology. Dr. Resch earned her Ph.D. in Biochemistry from the University of California, Los Angeles and completed a postdoctoral fellowship in Genomics and Bioinformatics at the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.
Hakan Sakul, Ph.D.
Vice President, Head of Diagnostics, Worldwide Research, Development and Medical
Hakan leads Pfizer’s company-wide Diagnostics efforts. He worked in the biotech industry in human genetics and statistical genetics fields early in his career before moving to Parke-Davis Pharmaceuticals to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Parke-Davis with Pfizer, he has held positions of increasing responsibility, including Director/Site Head for Clinical Pharmacogenomics, Senior Director in Molecular Profiling, and in Translational Oncology, and most recently as Executive Director of Diagnostics. Hakan interacted closely with Pfizer’s Executive Leadership Team and BOD to define and implement Pfizer’s current companion diagnostics strategy. One of his most significant professional accomplishments was to lead Pfizer’s flagship companion diagnostics program for Xalkori® (Crizotinib), resulting in simultaneous FDA approvals of the drug/diagnostic combination in 2011. He led Pfizer’s internal efforts that produced partnerships with several diagnostics companies. Hakan’s contributions to precision medicine and diagnostics have been widely recognized through both internal and external awards, frequent speaking engagements, and press coverage. He is a member of the BOD of Personalized Medicine Coalition and served on California Governor Brown’s Advisory Committee on Precision Medicine. After receiving BS and MSc degrees from Ankara University in Turkey, and PhD in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, he conducted postdoctoral studies at the University of California-Davis. He is the author of over 30 refereed scientific articles as well as many other papers, abstracts and book chapters. Hakan is keenly interested in diagnostics and related medical technologies to advance Precision Medicine for the improvement of individualized healthcare.
Eric E. Schadt, Ph.D.
Eric Schadt, Ph.D., is founder and CEO of Sema4, a patient-centered predictive health company built on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Dr. Schadt also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously Founding Director of the Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.
Dr. Schadt is an expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 350 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with the innovative Sema4 Health Intelligence Platform, Dr. Schadt is using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Steven Shak, M.D.
Chief Scientific Officer
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steven Shak, M.D., has served as Co-Founder, Chief Scientific Officer of Genomic Health since 2012 and was Chief Medical Officer from 2000 to 2013. Under Steve’s leadership, Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80 percent product development success rate.
Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in discovery research and medical affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.
Michael Sherman, M.D., M.B.A., M.S.
Chief Medical Officer, Senior Vice President
Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for health services for Harvard Pilgrim Health Care. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies, he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness.
Dr. Sherman serves as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). He also is the current chair for AHIP’s CMO Leadership Council, and serves on the board of directors for the Personalized Medicine Coalition, and on the board of advisors for the Harvard Business School Healthcare Initiative.
Prior to joining Harvard Pilgrim, Dr. Sherman served as corporate medical director, physician strategies for Humana, and he previously held leadership positions at UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies, which was purchased by UnitedHealth Group in 2003, Immusol, and Da Vita.
Dr. Sherman holds a B.A. in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania. He received his M.D. from Yale and M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management. In 2009, he was named a fellow of the American College of Physician Executives, and he currently serves on the faculty of the Department of Population Medicine at Harvard Medical School.
Don L. Siegel, M.D., Ph.D
Director, Division of Transfusion Medicine & Therapeutic Pathology and Director, Clinical Cell & Vaccine Production Facility
University of Pennsylvania Perelman School of Medicine
Don Siegel, M.D., Ph.D, is a Professor of Pathology & Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine and Director of the Division of Transfusion Medicine & Therapeutic Pathology at the Hospital of the University of Pennsylvania. He serves as the medical director of the blood bank and transfusion service; the apheresis/infusion unit, the hematopoietic stem cell processing laboratory; and the cellular and vaccine production facility.
Dr. Siegel received an undergraduate degree in biophysics from Brown University, a PhD in biophysics from Harvard University, and an MD from the University of Pennsylvania School of Medicine. He completed a residency in clinical pathology and fellowship in transfusion medicine at the Hospital of the University of Pennsylvania and joined the faculty at the University of Pennsylvania in 1991.
Dr. Siegel has expertise in the areas of blood transfusion, antibody and cellular therapy, therapeutic apheresis, and other related areas of transfusion medicine. His basic and translational research laboratory focuses on the discovery of recombinant human and non-human antibodies relevant to transfusion medicine, benign hematology, infectious diseases, and oncology, particularly for use in the design of targeted therapies such as chimeric antigen receptor T-cells.
Harpreet Singh, Ph.D.
Immatics Biotechnologies GmbH
Dr. Harpreet Singh co-founded Immatics in 2000 and Immatics US in 2015.
Since 2015, Dr. Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT) in close collaboration with MD Anderson Cancer Center.
Since 2000 he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapeutics with clinical utility. Dr. Singh has played a leading role in raising over US$230m of venture capital funding over several financing rounds and US$20m from the State of Texas CPRIT fund.
Dr. Singh is the inventor on numerous patents and patent applications and has co-authored approx. 30 publications in peer-reviewed journals including Nature Medicine, Nature Biotechnology, Lancet Oncology and Journal of Experimental Medicine, Brain and Blood. A scholar of Prof. Hans-Georg Rammensee, Dr. Singh completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.
Roy Smythe, M.D.
Roy Smythe, M.D., joined SomaLogic in November 2018 as CEO. Originally trained as a thoracic surgeon and physician-scientist, Dr. Smythe subsequently gained highly diverse experience and expertise across many areas of cutting-edge health care, technology and translational medicine.
Dr. Smythe came to SomaLogic from Royal Philips, where he served as Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based health care company. He held the same title previously at AVIA, a health care technology accelerator.
A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Dr. Smythe is also currently a member in more than 20 U.S. national learned societies.
Executive Vice President, Chief Operating Officer
Thermo Fisher Scientific
Mark Stevenson has been Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific since August 2017, with responsibility for Thermo Fisher’s life sciences, analytical instruments and laboratory products businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.
Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.
Mark received his MBA from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K.
Paul Stoffels, M.D.
Vice Chairman, Executive Committee; Chief Scientific Officer
Johnson & Johnson
Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.
Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all sectors to set the company-wide innovation agenda, discovering and developing transformational health care solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.
Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life sciences industry.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC’s Business Day programming, contributes to CNBC.com and is based at the network’s global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer’s, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master’s degree in journalism from Northwestern University and a bachelor’s degree in English and music from Wellesley College.
Alex Vadas, Ph.D.
Managing Director, Partner
Alexander Vadas is a Managing Director and Partner in L.E.K. Consulting’s Biopharmaceuticals and Life Sciences practice. He joined L.E.K. in 2000 and focuses on diagnostics, research tools and personalized medicine. Within those areas, Alexander has worked with a range of established and emerging clients in the areas of corporate strategy, product strategy, and planning and transaction support. He received both his BS and his Doctor of Philosophy in chemical engineering from the University of California, Los Angeles.
Liisa-Maria Voipio-Pulkki, M.D., Ph.D.
Director General, Chief Medical Officer
Ministry of Social Affairs and Health, Finland
Dr. Liisa-Maria Voipio-Pulkki is currently serving as the Director General of Strategic Affairs and Chief Medical Officer of the Finnish Ministry of Social Affairs and Health. She joined the Ministry in 2010 as the Director of the Health Care Group. Previously she was employed as the Senior Medical Adviser of the Finnish Association of Local and Regional Authorities in 2004-2009, Chief of Emergency and Acute Care of the Helsinki University Hospital District in 2000-2004 and as a specialist and Adjunct Professor of Medicine in the University of Turku, Finland. She is a specialist in internal medicine and cardiology and has published over 100 original papers in cardiovascular medicine. Since 2014 she has been actively involved in the Finnish Government’s “Health Growth Strategy” of personalized medicine and national competence clusters. In 2017 she was elected to chair the Steering Committee of the European Observatory on Health Systems and Policies, a WHO hosted partnership supporting evidence-informed health policy making. She resides in Helsinki and is actively involved in the preparations of the Finnish EU Presidency during the second half of 2019.
Jay G. Wohlgemuth, M.D.
Chief Medical Officer, Senior Vice President
Dr. Wohlgemuth oversees R&D, Medical, Employee Health and Employer Health and Wellness for Quest Diagnostics and is a member of the senior management team. Prior to joining Quest Diagnostics Dr. Wohlgemuth held the position of Director of Clinical Diagnostics, Immunology, Tissue Growth and Repair at Genentech as well as Global Development Team Leader – Ocrulizumab. He was co-founder and Chief Medical Officer for the molecular diagnostics company XDx, where he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. Jay obtained his bachelor’s degree in biology at Harvard College and received his medical degree from Stanford where he also served a fellowship in cardiovascular medicine. He is on the Board of Directors of the Personalized Medicine Coalition, Q2 Solutions and Diagnostic Labs of Oklahoma and serves as trustee of the Anne and Henry Zarrow Foundation, a charitable foundation focused on supporting delivering health care and social services.
Raquel Yotti, M.D., Ph.D.
General Director, Instituto de Salud Carlos III
Raquel Yotti is the current Director General of the Spanish Institute of Health “Carlos III”, the main public funding organization for biomedical research in Spain. She is a clinical cardiologist and an expert in cardiac imaging and inherited heart disease. Until her appointment in September 2018, she was the head of the Clinical Cardiology Department at the Gregorio Maranon General University Hospital, and associate professor of the Department of Bio-engineering and Aerospace Engineering at the Carlos III University in Madrid.